Cargando…
Comparing drug safety of hepatitis C therapies using post-market data
BACKGROUND: Hepatitis C affects about 3 % of the world’s population. In the United States, about 3.5 million have chronic hepatitis C, and it is the leading cause of liver cancer and the most common indication for liver transplantation. In the last decades, new advances in therapy have substantially...
Autores principales: | Huang, Jing, Zhang, Xinyuan, Tong, Jiayi, Du, Jingcheng, Duan, Rui, Yang, Liu, Moore, Jason H., Tao, Cui, Chen, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686214/ https://www.ncbi.nlm.nih.gov/pubmed/31391106 http://dx.doi.org/10.1186/s12911-019-0860-6 |
Ejemplares similares
-
Comparing Different Adverse Effects Among Multiple Drugs Using FAERS Data
por: Huang, Jing, et al.
Publicado: (2017) -
Characterization of the Differential Adverse Event Rates by Race/Ethnicity Groups for HPV Vaccine by Integrating Data From Different Sources
por: Huang, Jing, et al.
Publicado: (2018) -
Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
por: Luo, Chongliang, et al.
Publicado: (2022) -
Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023) -
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
por: Li, Chunxiao, et al.
Publicado: (2018)